Home - Australian Pharmacist

Pruritus in adult palliative care patients

AP Staff - November 7, 2000

Clinical

References Chaing HC, Huang V, Cornelius LA. Cancer and itch. Seminars in cutaneous medicine and surgery 2011;30(2):107–12. Weisshaar E, Dalgard F. Epidemiology of itch:...

Don’t leave me on my own!

AP Staff - January 30, 2000

Industry

References Pharmaceutical Society of Australia. Professional practice standards 2023, Version 6. 2023. At: www.psa.org.au/wp-content/uploads/2023/07/5933-Professional-Practice-Standards_FINAL-1.pdf Pharmaceutical Society of Australia. Professional practice standards implementation program. 2023....

Beyond the pills: navigating depression and antidepressant use for older adults

AP Staff - December 5, 2000

CPD

References Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Geronto 1986;5(1–2):165–73. Australian Institute of Health...

Supporting environmental sustainability – what can you do to help?

AP Staff - December 12, 2000

Advertorial

Advice and practical tips on how pharmacists can help lead positive change. How are climate change and health connected? Healthcare may not be the first thing...

SGLT2 inhibitors in heart failure

AP Staff - February 20, 2000

CPD

References McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur...

Aus CVD risk: the Australian cardiovascular disease risk calculator

AP Staff - February 20, 2000

CPD

References Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. 2024. At: www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/impacts/expenditure-cvd Australian Bureau of Statistics. Causes of Death,...

1...288289290 291 Page 289 of 291

Pharmacist of the Year – Ammar Altayib MPS

Lifetime Achievement Award – David North OAM MPS

Early Career Pharmacist of the Year – Lily Pham MPS

Intern of the Year – Peter Figliuzzi

Could Australia follow suit?

What does the TGA advise?

Will GLP-1 RAs be subsidised for weight loss?

What could LGBTQIA+ discrimination look like in a pharmacy setting?

What’s the impact?

What makes a pharmacy a welcoming and safe environment for LGBTQIA+ patients?

What challenges do LGBTQIA+ pharmacists face in the workplace?

Does your pharmacy warrant a ‘Rainbow Tick’?

What’s changing?

When does this change come into effect?

What’s the reason for the change?

If I record in practice management software, do I need to do anything differently?

Will there be further changes to practice software after 1 March?

Will I need to do anything differently if I enter vaccination directly into AIR via PRODA?

Does this mean pharmacists need to ask about pregnancy for every vaccination event?

What impact does a Wegovy have on cardiovascular risk?

What makes a patient eligible for Wegovy for cardiovascular disease?

What other cardiovascular risk factors does Wegovy help to mitigate?

Has a submission been made to PBAC?

What are the benefits for high-risk CVD patients with multimorbidities?

How long should cardiovascular patients stay on Wegovy?

Should other cardiovascular medicines be titrated if Wegovy is initiated?

What do patients need to know about adverse effects?

What complimentary lifestyle advice should pharmacists provide?

Pharmacist of the Year – Ammar Altayib MPS

Lifetime Achievement Award – David North OAM MPS

Early Career Pharmacist of the Year – Lily Pham MPS

Intern of the Year – Peter Figliuzzi

Could Australia follow suit?

What does the TGA advise?

Will GLP-1 RAs be subsidised for weight loss?

What could LGBTQIA+ discrimination look like in a pharmacy setting?

What’s the impact?

What makes a pharmacy a welcoming and safe environment for LGBTQIA+ patients?

What challenges do LGBTQIA+ pharmacists face in the workplace?

Does your pharmacy warrant a ‘Rainbow Tick’?

What’s changing?

When does this change come into effect?

What’s the reason for the change?

If I record in practice management software, do I need to do anything differently?

Will there be further changes to practice software after 1 March?

Will I need to do anything differently if I enter vaccination directly into AIR via PRODA?

Does this mean pharmacists need to ask about pregnancy for every vaccination event?

What impact does a Wegovy have on cardiovascular risk?

What makes a patient eligible for Wegovy for cardiovascular disease?

What other cardiovascular risk factors does Wegovy help to mitigate?

Has a submission been made to PBAC?

What are the benefits for high-risk CVD patients with multimorbidities?

How long should cardiovascular patients stay on Wegovy?

Should other cardiovascular medicines be titrated if Wegovy is initiated?

What do patients need to know about adverse effects?

What complimentary lifestyle advice should pharmacists provide?

Pharmacist of the Year – Ammar Altayib MPS

Lifetime Achievement Award – David North OAM MPS

Early Career Pharmacist of the Year – Lily Pham MPS

Intern of the Year – Peter Figliuzzi

Could Australia follow suit?

What does the TGA advise?

Will GLP-1 RAs be subsidised for weight loss?

What could LGBTQIA+ discrimination look like in a pharmacy setting?

What’s the impact?

What makes a pharmacy a welcoming and safe environment for LGBTQIA+ patients?

What challenges do LGBTQIA+ pharmacists face in the workplace?

Does your pharmacy warrant a ‘Rainbow Tick’?

What’s changing?

When does this change come into effect?

What’s the reason for the change?

If I record in practice management software, do I need to do anything differently?

Will there be further changes to practice software after 1 March?

Will I need to do anything differently if I enter vaccination directly into AIR via PRODA?

Does this mean pharmacists need to ask about pregnancy for every vaccination event?

What impact does a Wegovy have on cardiovascular risk?

What makes a patient eligible for Wegovy for cardiovascular disease?

What other cardiovascular risk factors does Wegovy help to mitigate?

Has a submission been made to PBAC?

What are the benefits for high-risk CVD patients with multimorbidities?